News

These findings indicate that lower ambient solar radiation is linked with more frequent systemic psoriasis therapy.

Aldeyra announces intention to resubmit NDA with new trial data in mid-year 2025.

The March 2025 month in review spotlights an RX Review about USMSTF guidance on bowel prep for colonoscopy, an FDA approval, and clinical trial updates.

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

The treatment for wet age-related macular degeneration failed to achieve its primary endpoint in both trials.

Blieden discusses long-term patient management in glaucoma, the importance of follow-up care, and the role of advocacy in ophthalmology.

Blieden describes recent advancements in the detection and treatment of narrow-angle glaucoma at TOA 2025.

McCulley examines the latest updates on GLP-1 receptor agonists relevant for ophthalmologists and patients with ophthalmic diseases at TOA 2025.

Participants with higher baseline eosinophil levels had the greatest responses and no participants experienced peaks of over 3000 eosinophils/µL.

Test your knowledge below on pooled data from ADvocate1 and ADvocate2 trials and stay up to date with the latest clinical advancements in atopic dermatitis treatment.

Hosts discuss how recent advances in HFpEF have changed discussions surrounding how cardiologists should approach treatment sequencing.

Follow-up to BALATON/COMINO indicates maintained improvement in best-corrected visual acuity and central subfield thickness 72 weeks after treatment.

Bariatric surgery was associated with improved overall survival at an acceptable health care cost within a 10-year horizon.

The FDA granted fast-track status to Biogen’s BIIB080, a tau-targeting therapy for Alzheimer Disease, which is now being evaluated in the global phase 2 CELIA study.

In this literature review, investigators concluded that subcutaneous injections of methotrexate have some advantages over oral therapy.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Study draws correlative connection between semaglutide and nonarteritic anterior ischemic optic neuropathy, more data required to show causation.

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

March highlights groundbreaking advancements in ophthalmology, including FDA approvals for innovative treatments and alarming findings on pediatric eye health post-COVID.

These data highlight the susceptibility loci shared between HS and other inflammatory diseases among those with this condition.

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.

HCPLive spoke with Levine about what is moving in the psychiatry pipeline and what is to come.

Ahmad Masri, MD, MS, discusses how new options change the historic approach to the treatment of newly diagnosed ATTR-CM.

Study findings suggest COVID-19 is linked to a greater risk of long-term kidney dysfunction and new-onset advanced CKD than influenza.

Daniel Judge, MD, discusses data from a prespecified analysis of ATTRibute-CM examining the effects of acoramidis with and without concomitant tafamidis use.

Research presents a correlation between the index and age-related macular degeneration and suggests a causal relationship.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.